Published in Gene Therapy Weekly, November 13th, 1995
Currently, Alzheimer's disease cannot be conclusively diagnosed until after the patient dies. A possible diagnostic approach would be to develop a premortem brain scan that could allow for semiquantitation of the A(beta) amyloid burden in human brain.
A study by J.E. Maggio et al., published in the 1992 Proceedings of the National Academy of Sciences (89:5462-66), using frozen postmortem sections of AD brain showed that 125I-labeled A(beta)1-40...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.